info:eu-repo/semantics/article
Activation of zebrafish Src family kinases by the prion protein is an amyloid-beta-sensitive signal that prevents the endocytosis and degradation of
Fecha
2016Institución
Resumen
BACKGROUND: Prions and amyloid-beta (Abeta) oligomers trigger neurodegeneration by hijacking a poorly understood cellular signal mediated by the prion protein (PrP) at the plasma membrane. In early zebrafish embryos, PrP-1-dependent signals control cell-cell adhesion via a tyrosine phosphorylation-dependent mechanism. RESULTS: Here we report that the Src family kinases (SFKs) Fyn and Yes act downstream of PrP-1 to prevent the endocytosis and degradation of
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Putative Role of the Aldo-Keto Reductase from Trypanosoma cruzi in Benznidazole Metabolism
Garavaglia, Patricia Andrea; Garavaglia, Patricia Andrea; Garavaglia, Patricia Andrea; Garavaglia, Patricia Andrea; Garavaglia, Patricia Andrea; Laverriere, Marc; Laverriere, Marc; Laverriere, Marc; Laverriere, Marc; Laverriere, Marc; Cannata, Joaquin Juan Bautista; Cannata, Joaquin Juan Bautista; Cannata, Joaquin Juan Bautista; Cannata, Joaquin Juan Bautista; Cannata, Joaquin Juan Bautista; Garcia, Gabriela Andrea; Garcia, Gabriela Andrea; Garcia, Gabriela Andrea; Garcia, Gabriela Andrea; Garcia, Gabriela Andrea (American Society for MicrobiologyAmerican Society for MicrobiologyAmerican Society for MicrobiologyAmerican Society for MicrobiologyAmerican Society for Microbiology, 2016-05)Benznidazole (Bz), the drug used for treatment of Chagas' disease (caused by the protozoan Trypanosoma cruzi), is activated by a parasitic NADH-dependent type I nitroreductase (NTR I). However, several studies have shown ... -
A circunferência do pescoço como marcador da resistência à insulina e síndrome metabólica : BRAMS: Brazilian Metabolic Syndrome Study
Stabe, Christiane França Camargo, 1973 -
Effects of short- and long-term Mediterranean-based dietary treatment on plasma LC-QTOF/MS metabolic profiling of subjects with metabolic syndrome features: The Metabolic Syndrome Reduction in Navarra (RESMENA) randomized controlled trial
Bondia-Pons I.; Martinez J.A.; de la Iglesia R.; Lopez-Legarrea P.; Poutanen K.; Hanhineva K.; Zulet M.D.L.A. (Wiley-VCH Verlag, 2015)